Advancing small molecules from R&D to GMP requires coordinated strategies to support phase I clinical manufacturing.
From his time in the industry before the contemporary good manufacturing practice (cGMP), senior drug substance consultant at DSI, a ProductLife Group company, Dave Adams quickly grasped the necessity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results